Biogen Stock News

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7 12 0 0 Last 30D 0 1

Biogen (BIIB) has laid off more than 100 workers -- the vast majority in its Alzheimers division -- as a result of the commercial failure of its Alzheimers treatment Aduhelm.

Biogen stock popped Thursday after an analyst suggested it could reap $8 billion in sales of its Alzheimer''s treatments.

Shares of Biogen Inc. were up 1.0% in trading on Thursday after the company confirmed to media outlets that it is laying off some U.S. employees as part of an effort to secure $500 million in annual cost savings. Stat first reported the layoffs, saying the company plans to cut 1,000 jobs, citing anonymous sources. The company had 9,610 employees, as of Dec. 31, according to its most recent 10-K. A Biogen spokesperson confirmed the layoffs but said it is not providing additional details. "The $500 million cost-savings will not be entirely driven by headcount," the spokesperson said in an email. "As part of our headcount reductions, we''ve prioritized not fulfilling open positions…Some employees will be able to apply for the open positions we are filling." Biogen has been betting that its Aduhelm, its new Alzheimer''s disease drug, would be a boon for the company; however, there have been questions about the approval process and the therapy''s effectiveness. Aduhelm generated $3 million in 2021.

Biogen’s largest-ever corporate restructuring began Wednesday, as employees around the world got word they would be laid off by the struggling biotech company.

Sens. Susan Collins and Shelley Moore Capito are asking the Centers for Medicare and Medicaid Services to not restrict patient access to Biogen Aduhelm for Alzheimers.

Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago q

Upgrades For Douglas Emmett Inc (NYSE: DEI ), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago quarter EPS of $0.40. At the moment, the stock has a 52-week-high of $36.97 and a 52-week-low of $29.38. Douglas Emmett closed at $32.18 at the end of the last trading period. According to Evercore ISI Group, the prior rating for Southwest Airlines Co (NYSE: LUV ) was changed from In-Line to Outperform. In the fourth quarter, Southwest Airlines showed an EPS of $0.14, compared to $1.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $64.75 and a 52-week-low of $38.66. Southwest Airlines closed at $42.32 at the end of the last trading period. According to DA Davidson, the prior rating for SciPlay Corp (NASDAQ: SCPL ) was changed from Neutral to Buy. SciPlay earned $0.09 in the fourth quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $22.29 and a 52-week-low of $10.75.

Biogen (BIIB) shares are trading higher in the pre-market Thursday after RBC Capital Markets upgraded the battered Alzheimer’s drug developer, citing an improving risk-reward…

Here are the biggest calls on Wall Street on Thursday.

Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading. Needham cut C3.ai, Inc. (NYSE: AI) price

Longleaf Partners Fund, a Memphis-based fund under Southeastern Asset Management, published its “Longleaf Partners Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded …

Key concerns centered on the drug's effectiveness and price.

Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its busi